Indaptus Therapeutics (NASDAQ:INDP – Get Free Report) announced its quarterly earnings results on Thursday. The company reported ($0.38) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.03, Zacks reports.
Indaptus Therapeutics Stock Performance
Shares of INDP stock opened at $0.81 on Thursday. The stock’s fifty day moving average is $0.86 and its 200-day moving average is $1.09. Indaptus Therapeutics has a 52 week low of $0.70 and a 52 week high of $3.10. The stock has a market capitalization of $11.45 million, a PE ratio of -0.48 and a beta of 1.60.
Analyst Upgrades and Downgrades
Separately, Maxim Group reduced their price target on shares of Indaptus Therapeutics from $8.00 to $5.00 and set a “buy” rating on the stock in a research report on Wednesday, November 13th.
Indaptus Therapeutics Company Profile
Indaptus Therapeutics, Inc, a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial.
Featured Stories
- Five stocks we like better than Indaptus Therapeutics
- Growth Stocks: What They Are, Examples and How to Invest
- Is a Bottom Finally Forming in Rocket Lab Stock?
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- Gold Rally vs. Oil Surge: Where Investors Are Betting Next
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Intel Stock Surges on New CEO – The Real Story Runs Deeper
Receive News & Ratings for Indaptus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indaptus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
